Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Japanese Journal of Ophthalmology
Published in: Japanese Journal of Ophthalmology 3/2016

01-05-2016 | Clinical Investigation

Clinical evaluation of the effect of diquafosol ophthalmic solution in glaucoma patients with dry eye syndrome

Authors: Sang Wook Jin, Ji Sang Min

Published in: Japanese Journal of Ophthalmology | Issue 3/2016

Login to get access

Abstract

Purpose

To investigate the effects of diquafosol on intraocular pressure (IOP) and dry eye symptoms in glaucoma patients with dry eye syndrome (DES).

Methods

This study evaluated a total of 138 glaucoma patients with DES who were treated with diquafosol ophthalmic solution (DIQUAS®). Before treatment and 1, 4, 12, 36, and 52 weeks after treatment, IOP, ocular surface disease index (OSDI), tear film break-up time (BUT), Schirmer I test scores, fluorescein staining, conjunctival impression cytology, and adverse drug reactions were evaluated.

Results

Throughout the treatment period, the mean IOP for all the patients remained stable after treatment with diquafosol (15.4 ± 2.8 mmHg at baseline and 16.0 ± 2.8 mmHg at 52 weeks). The mean OSDI score improved significantly at 4, 12, and 52 weeks after diquafosol treatment. The BUT and Schirmer I test scores were significantly increased after diquafosol treatment. The Oxford scheme score was significantly decreased at 1, 4, 12, 36, and 52 weeks after diquafosol treatment. A significant improvement in goblet cell density was observed after 4 weeks of treatment with diquafosol. Adverse drug reactions were reported in 22 (15.9 %) patients. There were no serious adverse drug reactions.

Conclusions

Diquafosol was effective in improving objective and subjective symptoms and maintained a stable IOP in glaucoma patients with DES. Therefore, the addition of diquafosol treatment in glaucoma patients with DES or ocular surface side effects using anti-glaucoma medication may be beneficial.
Literature
1.
2.
Ammar DA, Kahook MY. Effects of glaucoma medications and preservatives on cultured human trabecular meshwork and non-pigmented ciliary epithelial cell lines. Br J Ophthalmol. 2011;95:1466–9.CrossRefPubMed
3.
Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341–9.PubMed
4.
Lee SY, Wong TT, Chua J, Boo C, Soh YF, Tong L. Effect of chronic anti-glaucoma medications and trabeculectomy on tear osmolarity. Eye (London). 2013;27:1142–50.CrossRef
5.
Li Y, Kuang K, Yerxa B, Wen Q, Rosskothen H, Fischbarg J. Rabbit conjunctival epithelium transports fluid, and P2Y2 receptor agonists stimulate Cl- and fluid secretion. Am J Physiol Cell Physiol. 2001;281:595–602.
6.
Jumblatt JE, Jumblatt MM. Regulation of ocular mucin secretion by P2Y2 nucleotide receptors in rabbit and human conjunctiva. Exp Eye Res. 1998;67:341–6.CrossRefPubMed
7.
Murakami T, Fujihara T, Horibe Y, Nakamura M. Diquafosol elicits increases in net Cl- transport through P2Y2 receptor stimulation in rabbit conjunctiva. Ophthalmic Res. 2004;36:89–93.CrossRefPubMed
8.
Fujihara T, Murakami T, Nagano T, Nakamura M, Nakata K. INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model. J Ocul Pharmacol Ther. 2002;18:363–70.CrossRefPubMed
9.
Fujihara T, Murakami T, Fujita H, Nakamura M, Nakata K. Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci. 2001;42:96–100.PubMed
10.
Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K, Diquafosol Ophthalmic Solution Phase 2 Study Group. The efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. Ophthalmology. 2012;119:1954–60.CrossRefPubMed
11.
Takamura E, Tsubota K, Watanabe H, Ohashi Y, Diquafosol Ophthalmic Solution Phase 3 Study Group. A randomized, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol. 2012;96:1310–5.CrossRefPubMedPubMedCentral
12.
Koh S, Ikeda C, Takai Y, Watanabe H, Maeda N, Nishida K. Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye. Jpn J Ophthalmol. 2013;57:440–6.CrossRefPubMed
13.
Guzman-Aranquez A, Pintor J. Focus on molecules: purinergic P2Y(2) receptor. Exp Eye Res. 2012;105:83–4.CrossRef
14.
Martin-Gil A, de Lala MJ, Crooke A, Santano C, Peral A, Pintor J. Silencing of P2Y(2) receptors reduces intraocular pressure in New Zealand rabbits. Br J Pharmacol. 2012;165:1163–72.CrossRefPubMedPubMedCentral
15.
Pintor J, Peral A, Pelaez T, Martin S, Hoyle CH. Presence of diadenosine polyphosphates in the aqueous humor: their effect on intraocular pressure. J Pharmacol Exp Ther. 2003;304:342–8.CrossRefPubMed
16.
Behrens A, Doyle JJ, Stern L, Chuck RS, McDonnell PJ, Azar DT, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea. 2006;25:900–7.CrossRefPubMed
17.
Lemp MA, Baudouin C, Baum J, Dogru M, Foulks GN, Kinoshita S, et al. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop. Ocul Surf. 2007;5:75–92.CrossRef
18.
Schmidl D, Witkowska KJ, Kaya S, Baar C, Faatz H, Nepp J, et al. The association between subjective and objective parameters for the assessment of dry eye syndrome. Invest Ophthalmol Vis Sci. 2015;56:1467–72.CrossRefPubMed
19.
Miller KL, Walt JG, Mink DR, Satram-Hoang S, Wilson SE, Perry HD, et al. Minimal clinically important difference for the ocular surface disease index. Arch Ophthalmol. 2010;128:94–101.CrossRefPubMed
20.
Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003;22:640–50.CrossRefPubMed
21.
Lütjen-Drecoll E, Tamm E, Kaufman PL. Age changes in rhesus monkey ciliary muscle: light and electron microscopy. Exp Eye Res. 1988;47:885–99.CrossRefPubMed
22.
Fine BS, Yanoff M, Stone RA. A clinicopathologic study of four cases of primary open-angle glaucoma compared to normal eyes. Am J Ophtalmol. 1981;91:88–105.CrossRef
23.
Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002;120:330–7.CrossRefPubMed
24.
Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350–5.CrossRefPubMed
25.
Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153:1–9.CrossRefPubMed
26.
Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure lowering medications. Cornea. 2010;29:618–21.PubMed
Metadata
Title
Clinical evaluation of the effect of diquafosol ophthalmic solution in glaucoma patients with dry eye syndrome
Authors
Sang Wook Jin
Ji Sang Min
Publication date
01-05-2016
Publisher
Springer Japan
Published in
Japanese Journal of Ophthalmology / Issue 3/2016
Print ISSN: 0021-5155
Electronic ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-016-0430-8

Other articles of this Issue 3/2016

Japanese Journal of Ophthalmology 3/2016 Go to the issue

Clinical Investigation

Changes in corneal aberrations after cataract surgery

Clinical Investigation

Discrepancies in assessing anterior chamber activity among uveitis specialists

Clinical Investigation

The association between legal Japanese visual impairment grades and vision-related quality of life

Clinical Investigation

Genetic analysis of the aquaporin-4 gene for anti-AQP4 antibody-positive neuromyelitis optica in a Japanese population

Clinical Investigation

Short-term evaluation of Trabectome surgery performed on Japanese patients with open-angle glaucoma

Clinical Investigation

Comparison of retinal vessel measurements using adaptive optics scanning laser ophthalmoscopy and optical coherence tomography